- Home
- MFP vs ZYME Comparison
MFP vs ZYME Comparison
Compare MFP & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MFP | ZYME |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | MFP | ZYME |
|---|---|---|
| Price | $45.92 | $23.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | ★ 954.0K | 379.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $40.00 | $11.86 |
| 52 Week High | $49.86 | $29.75 |
Technical Indicators
Market Signals| Indicator | MFP | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 46.79 |
| Support Level | $44.47 | $22.20 |
| Resistance Level | $49.36 | $23.66 |
| Average True Range (ATR) | 3.05 | 0.91 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 63.96 | 53.40 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.